Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. Dec. 4, 2018. John Scandurra.

Executive Summary

Aria CV hopes to address pulmonary hypertension, a potential devastating condition that currently has few treatments, with a unique balloon device that requires no power supply, battery, pump, or synchronization. See what Aria CEO John Scandurra said about it here.

"We're on a unique pathway and the potential market is not limited to just pulmonary arterial hypertension, which is the target of drug therapy. We hope that our device can work in other classes of pulmonary hypertension as well, which really opens up into much bigger higher-prevalence markets." John Scandurra, CEO, Aria CV

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts